Abstract
Purpose: To determine the efficacy of pegylated interferon alfa-2A in the treatment of refractory inflammatory cystoid macular edema (CME) Methods: Retrospective chart review Results: Treatment with pegylated interferon alfa-2A led to an improvement in CME in all eyes of seven included patients, with a mean decrease in CMT from 478 µm to 310 µm (p <.05). The vision in one patient did not improve due to preexisting retinal atrophy. All other eyes showed improvement in vision, with a mean improvement in best LogMAR visual acuity from +0.59 to +0.28 (p <.05). The treatment effect was sustained with low-dose treatment every 2 weeks or less in the majority of patients. Two patients who stopped interferon treatment given flu-like symptoms and intolerable rash, respectively, showed rapid recurrence of CME. Conclusions: Weekly administration of pegylated interferon alfa-2A is an effective treatment for refractory inflammatory CME, though side effects may limit tolerability in some patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 566-571 |
| Number of pages | 6 |
| Journal | Ocular Immunology and Inflammation |
| Volume | 29 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2021 |
Keywords
- Pegylated interferon (peginterferon alfa-2A)
- cystoid macular edema
- uveitis
ASJC Scopus subject areas
- Immunology and Allergy
- Ophthalmology